Archives for April 2009

Identification Of New Therapeutic Target For Melanoma

A protein called Mcl-1 plays a critical role in melanoma cell resistance to a form of apoptosis called anoikis, according to research published this week in Molecular Cancer Research. The presence of Mcl-1 causes cell resistance to anoikis. This resistance to anoikis enables the melanoma cells to metastasize and survive at [...]

16 April 2009 | Uncategorized | No Comments

Topical Treatments For Chronic Plaque Psoriasis

Chronic plaque psoriasis is the most common type of psoriasis and is characterised by redness, thickness and scaling. First line management of chronic plaque psoriasis is with topical treatments, including vitamin D analogues, topical corticosteroids, tar-based preparations, dithranol, salicylic acid and topical retinoids.

16 April 2009 | Dermatology | No Comments

New Test Method To Measure Stored Heat In Firefighter Suits Developed By NC State

For decades, researchers have evaluated the thermal performance of protective clothing worn by firefighters. A particular area of current interest is how to address the burns received by firefighters when they are not directly in contact with fire - called stored heat burns. Researchers at North Carolina State University have developed a testing apparatus and [...]

16 April 2009 | Uncategorized | No Comments

Are Herbal Supplements Putting Aesthetic Surgery Patients At Risk?

For many people, the words “natural” or “herbal” are virtually synonymous with safety and purity. Products available over-the-counter without a doctor’s prescription are often mistakenly believed to be free of significant risks. A report in the March/April issue of Aesthetic Surgery Journal warns that more than 40% of plastic surgery patients [...]

16 April 2009 | Uncategorized | No Comments

Sciele Pharma Announces FDA Approval Of Benzyl Alcohol Lotion 5%, First Prescription Non-Neurotoxic Head Lice Treatment

Sciele Pharma, Inc., a Shionogi Company, announced that the U.S. Food & Drug Administration (FDA) has approved Benzyl Alcohol Lotion 5%, the first and only prescription medication that kills head lice by asphyxiation without potential neurotoxic side effects. Sciele acquired from Summers Laboratories the rights to this novel, patented product in the United States, Canada [...]

15 April 2009 | Uncategorized | No Comments

GRAFTJACKET(R) Regenerative Matrix Heals Diabetic Foot Ulcers More Effectively Than Standard Wound Management

Wright Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic medical device company, announced that peer-reviewed data from a prospective, randomized, controlled, multi-center study has been published online and will appear in the June 2009 issue of the International Wound Journal. The data confirms the effectiveness of the Company’s

15 April 2009 | Dermatology | No Comments

American Biotech Labs(R) Obtains FDA Approval For New Wound Care Gel Product

American Biotech Labs, LLC (ABL), developer of a new class of products based on the company’s patented nano-catalytic SilverSol Technology(R), announced that the company has been granted formal approval by the U.S. Food and Drug Administration (FDA) to market its ASAP Wound Dressing Gel throughout the United States.

15 April 2009 | Dermatology | No Comments

Bracelets, Labels With Intelligent Ink Could Warn Of Sunburn Danger

Scientists in the UK have developed UV-sensitive “intelligent inks” that change colour when there is danger of sunburn and can be tuned to suit different skin types, which is something that current UV dosimeters can’t cope with. However, they also said the challenge will not be cost or [...]

14 April 2009 | Uncategorized | No Comments

New Research Show’s GPs Struggle To Offer Recommended Levels Of Care To Children With

As recent research suggests a 42% rise in eczema during a five year period; could GP’s be doing more? GPs are struggling to provide the quality of care for children with eczema currently recommended by two of the UK’s most prestigious medical bodies: the National Institute of Health and Clinical Excellence [...]

14 April 2009 | Uncategorized | No Comments

Genentech Announces Voluntary Withdrawal Of Raptiva From The U.S. Market

Genentech, Inc. announced a phased voluntary withdrawal of the psoriasis drug Raptiva® (efalizumab) from the U.S. market. The company’s decision is based on the association of Raptiva with an increased risk of progressive multifocal leukoencephalopathy (PML), a rare and usually fatal disease of the central nervous system.

14 April 2009 | Dermatology | No Comments

Navigation

News Archives

Sponsors